Aripiprazole will show improved effectiveness over the standard of care treatment with one of
three atypical antipsychotics (olanzapine, quetiapine and risperidone).
Phase:
Phase 3
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.